Physician profile
Arjun Nanda
NPI 1346539806
$9,588.22
in general payments reported to CMS, 2019-2025
38 companies · $1,903 in 2025
The $1,903 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2020: $959 · 2021: $1,321 · 2022: $1,209 · 2023: $1,758 · 2024: $1,430 · 2025: $1,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,941 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,941.26 |
| Education | $149.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,466.12 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,582.52 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $941.36 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $776.49 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Gilead Sciences, INC. | $635.14 | 2019-2025 | |
| Kerecis Limited | $548.46 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Surgiclose, Kerecis Omega3 Marigen |
| Celgene Corporation | $367.95 | 2021-2024 | Zeposia |
| Genzyme Corporation | $296.62 | 2023-2025 | |
| Pfizer INC. | $253.73 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $182.74 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $159.58 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $152.70 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $106.02 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $104.88 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $103.46 | 2024-2025 | Omvoh |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $98.74 | 2024-2025 | Resmetirom, Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $75.52 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $74.99 | 2025 | Zenpep, Vowst |
| Allergan, INC. | $72.46 | 2019-2020 | |
| Vivus LLC | $68.17 | 2020-2021 | |
| Redhill Biopharma INC. | $66.42 | 2021-2023 | Talicia, Aemcolo |
| Nestle Healthcare Nutrition INC. | $54.63 | 2021-2023 | |
| Access Pro Medical, LLC | $48.06 | 2025 | Matriderm |
| Celltrion USA INC. | $47.16 | 2024-2025 | Zymfentra, Vegzelma |
| Stryker Corporation | $33.16 | 2025 | Neptune |
| Shield Therapeutics INC | $27.29 | 2025 | |
| Ucb, INC. | $26.86 | 2019 | |
| Merck Sharp & Dohme LLC | $26.16 | 2020-2021 | |
| Braintree Laboratories, INC. | $25.40 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $21.28 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $21.16 | 2023 | Andexxa |
| Novo Nordisk INC | $21.03 | 2025 | Wegovy |
| Horizon Therapeutics Plc | $20.84 | 2020 | |
| Shionogi INC | $20.38 | 2019 | |
| Portola Pharmaceuticals, LLC | $17.88 | 2019 | |
| Exact Sciences Corporation | $16.40 | 2023 | Cologuard Collection Kit |
| Alfasigma USA, INC. | $14.94 | 2020 | |
| Ethicon US, LLC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Nanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.